Epidemiological, clinical, and public health response characteristics of a large outbreak of diphtheria among the Rohingya population in Cox's Bazar, Bangladesh, 2017 to 2019: A retrospective study.
Adolescent
Adult
Aged
Aged, 80 and over
Bangladesh
/ epidemiology
Child
Child, Preschool
Diphtheria
/ epidemiology
Disease Outbreaks
/ prevention & control
Humans
Infant
Infant, Newborn
Male
Middle Aged
Public Health
Refugee Camps
Refugees
Retrospective Studies
Vaccination
/ statistics & numerical data
Young Adult
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
02
09
2020
accepted:
15
03
2021
revised:
21
04
2021
pubmed:
2
4
2021
medline:
12
8
2021
entrez:
1
4
2021
Statut:
epublish
Résumé
Unrest in Myanmar in August 2017 resulted in the movement of over 700,000 Rohingya refugees to overcrowded camps in Cox's Bazar, Bangladesh. A large outbreak of diphtheria subsequently began in this population. Data were collected during mass vaccination campaigns (MVCs), contact tracing activities, and from 9 Diphtheria Treatment Centers (DTCs) operated by national and international organizations. These data were used to describe the epidemiological and clinical features and the control measures to prevent transmission, during the first 2 years of the outbreak. Between November 10, 2017 and November 9, 2019, 7,064 cases were reported: 285 (4.0%) laboratory-confirmed, 3,610 (51.1%) probable, and 3,169 (44.9%) suspected cases. The crude attack rate was 51.5 cases per 10,000 person-years, and epidemic doubling time was 4.4 days (95% confidence interval [CI] 4.2-4.7) during the exponential growth phase. The median age was 10 years (range 0-85), and 3,126 (44.3%) were male. The typical symptoms were sore throat (93.5%), fever (86.0%), pseudomembrane (34.7%), and gross cervical lymphadenopathy (GCL; 30.6%). Diphtheria antitoxin (DAT) was administered to 1,062 (89.0%) out of 1,193 eligible patients, with adverse reactions following among 229 (21.6%). There were 45 deaths (case fatality ratio [CFR] 0.6%). Household contacts for 5,702 (80.7%) of 7,064 cases were successfully traced. A total of 41,452 contacts were identified, of whom 40,364 (97.4%) consented to begin chemoprophylaxis; adherence was 55.0% (N = 22,218) at 3-day follow-up. Unvaccinated household contacts were vaccinated with 3 doses (with 4-week interval), while a booster dose was administered if the primary vaccination schedule had been completed. The proportion of contacts vaccinated was 64.7% overall. Three MVC rounds were conducted, with administrative coverage varying between 88.5% and 110.4%. Pentavalent vaccine was administered to those aged 6 weeks to 6 years, while tetanus and diphtheria (Td) vaccine was administered to those aged 7 years and older. Lack of adequate diagnostic capacity to confirm cases was the main limitation, with a majority of cases unconfirmed and the proportion of true diphtheria cases unknown. To our knowledge, this is the largest reported diphtheria outbreak in refugee settings. We observed that high population density, poor living conditions, and fast growth rate were associated with explosive expansion of the outbreak during the initial exponential growth phase. Three rounds of mass vaccinations targeting those aged 6 weeks to 14 years were associated with only modestly reduced transmission, and additional public health measures were necessary to end the outbreak. This outbreak has a long-lasting tail, with Rt oscillating at around 1 for an extended period. An adequate global DAT stockpile needs to be maintained. All populations must have access to health services and routine vaccination, and this access must be maintained during humanitarian crises.
Sections du résumé
BACKGROUND
Unrest in Myanmar in August 2017 resulted in the movement of over 700,000 Rohingya refugees to overcrowded camps in Cox's Bazar, Bangladesh. A large outbreak of diphtheria subsequently began in this population.
METHODS AND FINDINGS
Data were collected during mass vaccination campaigns (MVCs), contact tracing activities, and from 9 Diphtheria Treatment Centers (DTCs) operated by national and international organizations. These data were used to describe the epidemiological and clinical features and the control measures to prevent transmission, during the first 2 years of the outbreak. Between November 10, 2017 and November 9, 2019, 7,064 cases were reported: 285 (4.0%) laboratory-confirmed, 3,610 (51.1%) probable, and 3,169 (44.9%) suspected cases. The crude attack rate was 51.5 cases per 10,000 person-years, and epidemic doubling time was 4.4 days (95% confidence interval [CI] 4.2-4.7) during the exponential growth phase. The median age was 10 years (range 0-85), and 3,126 (44.3%) were male. The typical symptoms were sore throat (93.5%), fever (86.0%), pseudomembrane (34.7%), and gross cervical lymphadenopathy (GCL; 30.6%). Diphtheria antitoxin (DAT) was administered to 1,062 (89.0%) out of 1,193 eligible patients, with adverse reactions following among 229 (21.6%). There were 45 deaths (case fatality ratio [CFR] 0.6%). Household contacts for 5,702 (80.7%) of 7,064 cases were successfully traced. A total of 41,452 contacts were identified, of whom 40,364 (97.4%) consented to begin chemoprophylaxis; adherence was 55.0% (N = 22,218) at 3-day follow-up. Unvaccinated household contacts were vaccinated with 3 doses (with 4-week interval), while a booster dose was administered if the primary vaccination schedule had been completed. The proportion of contacts vaccinated was 64.7% overall. Three MVC rounds were conducted, with administrative coverage varying between 88.5% and 110.4%. Pentavalent vaccine was administered to those aged 6 weeks to 6 years, while tetanus and diphtheria (Td) vaccine was administered to those aged 7 years and older. Lack of adequate diagnostic capacity to confirm cases was the main limitation, with a majority of cases unconfirmed and the proportion of true diphtheria cases unknown.
CONCLUSIONS
To our knowledge, this is the largest reported diphtheria outbreak in refugee settings. We observed that high population density, poor living conditions, and fast growth rate were associated with explosive expansion of the outbreak during the initial exponential growth phase. Three rounds of mass vaccinations targeting those aged 6 weeks to 14 years were associated with only modestly reduced transmission, and additional public health measures were necessary to end the outbreak. This outbreak has a long-lasting tail, with Rt oscillating at around 1 for an extended period. An adequate global DAT stockpile needs to be maintained. All populations must have access to health services and routine vaccination, and this access must be maintained during humanitarian crises.
Identifiants
pubmed: 33793554
doi: 10.1371/journal.pmed.1003587
pii: PMEDICINE-D-20-04270
pmc: PMC8059831
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003587Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Proc Biol Sci. 2007 Feb 22;274(1609):599-604
pubmed: 17476782
Philos Trans R Soc Lond B Biol Sci. 2019 Jul 8;374(1776):20180276
pubmed: 31104603
J Clin Microbiol. 2020 Sep 22;58(10):
pubmed: 32727830
Emerg Infect Dis. 2019 Oct;25(10):1834-1842
pubmed: 31538559
MMWR Morb Mortal Wkly Rep. 1996 Apr 5;45(13):271-3
pubmed: 8596528
Front Public Health. 2017 Aug 30;5:218
pubmed: 28913330
Nat Rev Dis Primers. 2019 Dec 5;5(1):81
pubmed: 31804499
MMWR Morb Mortal Wkly Rep. 1999 Apr 2;48(12):243-8
pubmed: 10220251
Lancet. 2018 Dec 23;390(10114):2740
pubmed: 29303713
Epidemics. 2019 Dec;29:100356
pubmed: 31624039
Emerg Infect Dis. 2018 Nov;24(11):2074-2076
pubmed: 30234479
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
Am J Trop Med Hyg. 2018 May;98(5):1214-1215
pubmed: 29611508
Health Hum Rights. 2018 Dec;20(2):105-122
pubmed: 30568406
Epidemics. 2018 Mar;22:29-35
pubmed: 28351674
Emerg Infect Dis. 2019 Apr;25(4):625-632
pubmed: 30698523
Southeast Asian J Trop Med Public Health. 2010 May;41(3):647-52
pubmed: 20578554
Philos Trans R Soc Lond B Biol Sci. 2019 Jul 8;374(1776):20180431
pubmed: 31104606
Trans R Soc Trop Med Hyg. 2020 Sep 1;114(9):635-638
pubmed: 32585031
BMC Med. 2019 Mar 12;17(1):58
pubmed: 30857521
Emerg Infect Dis. 1998 Oct-Dec;4(4):539-50
pubmed: 9866730
Epidemiol Bull. 2001 Sep;22(3):13-5
pubmed: 11797234
Wkly Epidemiol Rec. ;92(31):417-35
pubmed: 28776357
PLoS Med. 2013 Nov;10(11):e1001544
pubmed: 24223523
J Infect Dis. 2000 Feb;181 Suppl 1:S116-20
pubmed: 10657202
Vaccine. 2016 Aug 5;34(36):4321-6
pubmed: 27422343
Clin Infect Dis. 2020 Jun 24;71(1):89-97
pubmed: 31425581
Eur J Epidemiol. 1995 Feb;11(1):107-17
pubmed: 7489768
Confl Health. 2019 May 22;13:19
pubmed: 31139250
J Travel Med. 2019 Jan 1;26(1):
pubmed: 30407562
Epidemiol Infect. 2014 Apr;142(4):797-802
pubmed: 23866913
Rev Panam Salud Publica. 2015 Oct;38(4):292-9
pubmed: 26758220
PLoS Med. 2020 Mar 31;17(3):e1003071
pubmed: 32231368
J Neurol Neurosurg Psychiatry. 1999 Oct;67(4):433-8
pubmed: 10486387
Confl Health. 2013 Jan 22;7(1):1
pubmed: 23339463
Epidemiol Infect. 2017 Jul;145(10):2100-2108
pubmed: 28478776
Int J Infect Dis. 2018 Jun;71:122-123
pubmed: 29871739
Epidemiol Infect. 2015 Mar;143(4):791-8
pubmed: 25703400
J Infect Dis. 2000 Feb;181 Suppl 1:S138-45
pubmed: 10657205
Emerg Infect Dis. 2018 Jul;24(7):1340-1344
pubmed: 29912686
Vaccine. 2019 Feb 4;37(6):833-838
pubmed: 30642728
Pediatrics. 1985 Jul;76(1):1-9
pubmed: 3892472
Euro Surveill. 2014 Jun 19;19(24):
pubmed: 24970373
PeerJ. 2018 Apr 2;6:e4583
pubmed: 29629244
Am J Epidemiol. 2013 Nov 1;178(9):1505-12
pubmed: 24043437